ARCT

#3502
Arcturus Therapeutics Holdings Inc. Common Stock
8.75 USD
+3.43%
セクター: ヘルスケア
ベース: USD
利益通貨: USD
日中レンジ
8.63
8.75
1年のレンジ
5.86
24.14
1日の変化
+3.43%
月次変化
+28.87%
6か月変化
-58.90%
1年の変化
-15.05%
以前の終値
8.46
始値
8.64
Bid
Ask
安値
8.63
High
8.75
ボリューム
22
チャート全体を表示

Financials

概要 明細書 統計
期次 年次
  • Market Capitalization 248.7 M
  • Employee 111
  • Founded 2013
  • CEO Joseph E. Payne
  • Website www.arcturusrx.com
  • Headquarter Delaware, United States
  • FIGI BBG00NNW8JK1
  • Industry Technology
総売上高
当期純利益
1株当たり基本利益（基本EPS）
有利子負債合計
フリーキャッシュフロー
現金および現金同等物
株価収益率
-2.55
売上高対価格比率
2.05

Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA, messenger RNA, gene editing RNA, DNA, antisense oligonucleotides, and microRNA. The company develops RNA therapeutics for the treatment of rare diseases such as ornithine transcarbamylase deficiency, and respiratory diseases such as cystic fibrosis. Vaccine medicines include a vaccine candidate for COVID-19 and an influenza vaccine in the preclinical development phase. The vaccine for COVID-19 was authorised in Japan in 2023 and the European Union in 2025.

ニュース